Open an account

ARS Pharmaceuticals

SPRY · NASDAQ

$4.29+$0.06 (+1.42%)TodayMarket closed ·
Prev close $4.23

About SPRY

ARS Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on the development of a novel, potentially first-in-class product candidate, neffy, for the emergency treatment of Type I allergic reactions including anaphylaxis. The company is headquartered in San Diego, California and currently employs 158 full-time employees. The company went IPO on 2020-12-04. The firm is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. The company is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.

Employees
158
Headquarters
San Diego, California
Listed
Dec 4, 2020
Sector
Health Care
Industry
Biotechnology
Website
ars-pharma.com

SPRY key statistics

Market cap
426.63M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.49M
Volume
1.54M
Open price
$4.25
High today
$4.44
Low today
$4.23
52 Week high
$13.15
52 Week low
$3.81

ARS Pharmaceuticals (SPRY) at a glance

As of Oct 20, 2026, ARS Pharmaceuticals (SPRY) shares are priced at $4.29, giving the company a market cap of 426.63M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.23 and $4.44. The current price is 1.5% above the day's low and 3.4% below its high.

Volume so far is 1.54M shares, in line with the average of 1.49M shares a day.

Over the past year ARS Pharmaceuticals has ranged from $3.81 to $13.15, and now sits 5% of the way up that range.

ARS Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.63 per share against an estimate of -$0.5024.

The average analyst price target is $27.03, 530.1% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $27.03
Low
$15.15
Now
$4.29
High
$34.65

SPRY earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 113.7% on average.

  1. Q3 FY24: reported -$0.20 per share against an estimate of -$0.1505
  2. Q4 FY24: reported $0.49 per share against an estimate of -$0.1428
  3. Q1 FY25: reported -$0.35 per share against an estimate of -$0.3536
  4. Q2 FY25: reported -$0.46 per share against an estimate of -$0.4794
  5. Q3 FY25: reported -$0.52 per share against an estimate of -$0.4814
  6. Q4 FY25: reported -$0.42 per share against an estimate of -$0.4505
  7. Q1 FY26: reported -$0.61 per share against an estimate of -$0.536
  8. Q2 FY26: reported -$0.63 per share against an estimate of -$0.5024

SPRY news

  • Press releaseBusiness Wire

    SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

  • Press releasePRNewswire

    ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

  • Press releaseGlobe Newswire

    ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role

  • Press releaseNewsfile

    Kaplan Fox Class Action Reminder: ARS Pharmaceuticals Inc. (SPRY) Lead Plaintiff Deadline is October 5, 2026

  • Press releasePRNewswire

    SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

  • Press releasePRNewswire

    Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

  • Press releaseNewsfile

    Kaplan Fox Notifies Investors: Deadline to Lead in the ARS Pharmaceuticals Inc. (SPRY) Securities Class Action is October 5, 2026

  • Press releaseGlobe Newswire

    Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors

Similar companies

Companies in the same industry as ARS Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.